Proton Pump Inhibitors (PPIs) are a very popular class of medications generally regarded as safe. PPIs are used to treat heartburn and gastroesophageal reflux disease and include drugs such as Nexium and Prevacid. While adverse reactions to the drugs (such as kidney failure) are rare, those who do suffer will not experience any signs of kidney failure until the damage is severe.
A recent study in Kidney International (Feb 2017) that examined 125,000 users of PPIs found that those who did suffer from chronic or kidney failure did not have acute kidney problems prior. The findings suggest that patients need to be far more careful when using the medications that previously thought. Routine doctor check-ups should be the norm, even when using over-the-counter PPIs, according to the article.
Pharmacogenetics and PPIs
In addition to kidney failure, other adverse reactions from PPIs can occur in susceptible patients. Genetic variations of CYP2C19 give rise to poor and extensive metabolizer phenotypes. Rxight® genetic testing measures patients’ genotypically determined ability to metabolize proton pump inhibitors and 200 other clinically relevant medications across 50 pharmacological classes. The results of the Rxight® test will be reviewed in detail to guide you and your prescribers in finding the safest and most effective treatment for you.